BSPM Key Stats
- Biostar Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcrip... May 16
- Biostar Pharmaceuticals, Inc. Announces First Quarter 2013 Financial Results PR Newswire May 16
- BIOSTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 15
- Q1 2013 Biostar Pharmaceuticals Inc Earnings Release - After Market Close May 15
- Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2013 First Quarter Earnings Co... May 14
- BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure... May 6
- BIOSTAR PHARMACEUTICALS, INC. Financials Apr 19
- BIOSTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Fina... Apr 16
- BIOSTAR PHARMACEUTICALS, INC. REPORTS 2012 RESULTS noodls Apr 16
- Biostar Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcrip... Apr 15
BSPM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Biostar Pharmaceuticals is down 55.86% over the last year vs S&P 500 Total Return up 25.82%, Abbott Laboratories up 30.46%, and Daiichi Sankyo up 14.35%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for BSPM
Pro Strategies Featuring BSPM
Did Biostar Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.